AbbVie announced today that it has settled its patent litigation with Boehringer Ingelheim over adalimumab.
AbbVie announced today that it has settled its patent litigation with Boehringer Ingelheim (BI) over adalimumab.
Under the terms of the settlement, BI’s biosimilar, Cyltezo, will not enter the US market until July 1, 2023. BI will pay royalties to AbbVie for licensing of its patents covering the reference drug, Humira, and BI acknowledged the enforceability of AbbVie’s patents.
“This is an important settlement as it resolves all Humira-related patent litigation in the US and provides access for another biosimilar manufacturer seeking to enter the US,” said Laura Schumacher, vice chairman, external affairs, and chief legal officer at AbbVie, in a statement announcing the settlement. “As an innovation-driven biopharmaceutical company, we will continue to develop novel cures for the toughest health challenges and rely on a robust patent system to protect that investment in innovation.”
AbbVie first sued BI for patent infringement in 2017, saying that BI would infringe on more than 70 patents covering adalimumab in developing its biosimilar, which was approved just months later by the FDA under the brand name Cyltezo.
Then, in June 2018, the court granted BI’s motion to compel discovery in the case after BI argued that it needed relevant documents related to its allegations that AbbVie has “unclean hands”; the unclean hands doctrine is a legal defense that bars a party who is asking for a judgment from receiving the court’s help if that party has behaved unethically with respect to the subject of the lawsuit. According to BI, AbbVie’s strategy of acquiring what BI described at the time as overlapping, noninventive patents that create a patent “thicket” could constitute unclean hands on AbbVie’s part.
The settlement marks a turning point in the US biosimilars market, as BI was the only remaining biosimilar developer with an approved or late-stage product that had not yet reached an agreement with AbbVie. BI had previously told The Center for Biosimilars® that it was “committed to making [the biosimilar] available to US patients as soon as possible, and certainly before 2023.”
BI follows in the steps of Coherus, Pfizer, Amgen, Mylan, Samsung Bioepis, Sandoz, Fresenius Kabi, and Momenta, which also struck deals with the Humira maker. None of their products will enter the US market before 2023, either. First to enter will be Amgen’s biosimilar, Amjevita, in January 2023.
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD
February 15th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.